THE USE OF IMMUNOTHERAPY IN HCC
IN-DEPTH SUBGROUP ANALYSES AND CHALLENGES

The **Child-Pugh** and **ALBI** scoring systems are methods to assess liver function

CHILD-PUGH
Scoring system

Points

- Serum bilirubin
- Serum albumin
- Prothrombin INR
- Ascites
- Hepatic encephalopathy

+

Class

- **A** MILD
- **B** MODERATE
- **C** SEVERE

ALBI
Scoring system

Score

- Serum bilirubin
- Serum albumin

*

Grade

- **1** MILD
- **2** MODERATE
- **3** SEVERE

*ALBI score = −0.085 × (albumin g/L) + 0.66 × log(bilirubin μmol/L)

The ALBI scoring system is **more objective** and **easier to retrieve** than the Child–Pugh scoring system and helps to **further divide** patients with compensated cirrhosis into subgroups to **predict clinical outcome of IO in patients with HCC.**

Given the expanding treatment options, **including IO and IO combinations,** there is a need to understand whether **specific patient groups** benefit more from one therapy than another

Subgroup analyses on the efficacy and safety of IO combinations for patients with HCC

IO combination	**Atezolizumab (IO) + bevacizumab (anti-VEGF)** versus sorafenib[1]	**Tremelimumab (IO) + durvalumab (IO)** versus sorafenib[3]	
SUBGROUP: Liver function	**Median OS (months)[2]**	**OS hazard ratios[4]** (Favours treme + durva ← | → Favours sorafenib)	
	ALBI Grade **1**	**ALBI** Grade **1**	0.79
	Atezolizumab + bevacizumab >28*		
	Sorafenib 11.7		
	ALBI Grade **2**	**ALBI** Grade **2** **3**	0.83
	Atezolizumab + bevacizumab 15.4		
	Sorafenib 12.2	Full analysis set	0.78

THE SAFETY PROFILES ACROSS SUBGROUPS BASED ON LIVER FUNCTION WERE GENERALLY CONSISTENT

SUBGROUP: Etiology	**OS hazard ratios[1]** Favours atezo + bev ← | → Favours sorafenib		**OS hazard ratios[5]** Favours treme + durva ← | → Favours sorafenib	
All patients		0.66		0.77
HBV-HCC		0.58		0.64
HCV-HCC		0.43		1.06
Non-viral HCC		1.05		0.73

THERE ARE NOT ENOUGH MATURE DATA AVAILABLE TO GUIDE TREATMENT DECISIONS FOR THESE PATIENT SUBGROUPS

COR2ED
THE HEART OF MEDICAL EDUCATION

Go to COR2ED.COM for more information and resources

June 2023